Literature DB >> 31530588

Economic impact of delirium in Australia: a cost of illness study.

Lynne Pezzullo1, Jared Streatfeild2, Josiah Hickson1, Andrew Teodorczuk3, Meera R Agar4, Gideon A Caplan5,6.   

Abstract

OBJECTIVES: To estimate the economic impact of delirium in the Australian population in 2016-2017, including financial costs, and its burden on health. DESIGN, SETTING AND PARTICIPANTS: A cost of illness study was conducted for the Australian population in the 2016-2017 financial year. The prevalence of delirium in 2016-2017 was calculated to inform cost estimations. The costs estimated in this study also include dementia attributable to delirium. MAIN OUTCOME MEASURES: The total and per capita costs were analysed for three categories: health systems costs, other financial costs including productivity losses and informal care and cost associated with loss of well-being (burden of disease). Costs were expressed in 2016-2017 pound sterling (£) and Australian dollars ($A).
RESULTS: There were an estimated 132 595 occurrences of delirium in 2016-2017, and more than 900 deaths were attributed to delirium in 2016-2017. Delirium causes an estimated 10.6% of dementia in Australia. The total costs of delirium in Australia were estimated to be £4.3 billion ($A8.8 billion) in 2016-2017, ranging between £2.6 billion ($A5.3 billion) and £5.9 billion ($A12.1 billion). The total estimated costs comprised financial costs of £1.7 billion and the value of healthy life lost of £2.5 billion. Dementia attributable to delirium accounted for £2.2 billion of the total cost of delirium.
CONCLUSIONS: These findings highlight the substantial burden that delirium imposes on Australian society-both in terms of financial costs associated with health system expenditure and the increased need for residential aged care due to the functional and cognitive decline associated with delirium and dementia. To reduce the substantial well-being costs of delirium, further research should seek to better understand the potential pathways from an episode of delirium to subsequent mortality and reduced cognitive functioning outcomes. © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  delirium & cognitive disorders; dementia; health economics

Year:  2019        PMID: 31530588      PMCID: PMC6756419          DOI: 10.1136/bmjopen-2018-027514

Source DB:  PubMed          Journal:  BMJ Open        ISSN: 2044-6055            Impact factor:   2.692


This cost of illness study estimates the total annual financial and well-being impacts of delirium for the first time in Australia. This study also estimates the costs of dementia that are associated with delirium in Australia, with significant implications for other high-income western countries. This study is based on a non-systematic search strategy to find relevant cost inputs, noting that a number of inputs are sourced from official Australian Government statistics. There were a number of data gaps when estimating costs, meaning the results of this study are only indicative of the total cost. While this cost of illness study estimates the overall cost of delirium, more work is needed to identify cost-effective interventions to reduce the burden of delirium.

Introduction

Delirium is a common, serious and sometimes fatal medical condition, characterised by an acute decline in cognitive functioning.1 The term delirium is used to describe a transient, reversible neuropsychiatric syndrome that is of acute (abrupt or sudden) onset, with a fluctuating course which often occurs in the setting of a medical condition.2 The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition characterises delirium as a disturbance in attention, where the disturbance develops over a short period of time and represents an acute change from baseline attention and awareness. The disturbance should not be better explained by a pre-existing disorder, and evidence is required that the disturbance is a direct physiological consequence of another medical condition, substance intoxication or withdrawal or exposure to a toxin.3 The development of delirium has been associated with increased morbidity, persistent functional decline, higher hospital costs, higher rates of residential aged care placement and increased mortality.2 4 5 It is also a significant risk factor for later onset of dementia and acceleration of cognitive decline.4 Though underdiagnosed, it is highly prevalent in hospitalisations, particularly so for palliative care populations6 7; as many as 50% of people over the age of 65 who are admitted to hospital experience delirium depending on the clinical setting.2 Despite being preventable in more than a third of cases, a study in Sweden showed that delirium remains a common complication in hospitalised elderly patients.8 A previous study in the USA, undertaken over a decade ago, assessed the costs associated with delirium after adjusting for patient sociodemographic and clinical characteristics and found that hospital costs per day for patients with delirium were more than double the costs of patients who did not experience an episode of delirium.9 Additionally, previous studies have found associations between delirium and long-term cognitive impairment and dementia10 and premature death.3 11 However, the relative costs of these outcomes have not yet been established. To date, no studies have estimated the costs of delirium in Australia. Understanding the costs of delirium is important because delirium is often missed in as many as two-thirds of cases,12 although there are validated tools for diagnosing delirium such as the Confusion Assessment Method.2 By better understanding the costs, morbidity and mortality of delirium, it is possible to answer the question of whether it would be worthwhile to pay more attention to its prevention and diagnosis. Understanding the costs of delirium also helps to make informed decisions regarding treatment interventions. The purpose of this study was to raise awareness of the impacts of delirium and contribute to improving policy in this area by quantifying the magnitude of the economic burden associated with delirium in Australia in 2016–2017.

Methods

This cost of illness study was conducted using standard methodology,13 based on a prevalence approach to cost measurement. Prevalence approaches measure the number of people with a given condition in a base period and the costs associated with treating them, as well as other financial and non-financial costs in that year due to the condition. This approach was combined with both bottom-up and top-down approaches to estimate expenditure for each cost component.13 For example, a top-down approach was used to estimate the costs of dementia due to delirium, while most costs of delirium have been established using a bottom-up approach. The methodology is consistent with previously published research in this field in Australia and internationally.14–16 Costs were estimated from the perspective of Australian society for the 2016–2017 financial year. In this study, the financial costs of delirium to the Australian health system include the costs of running hospitals and nursing homes, general practitioner (GP) and specialist services reimbursed through Australia’s universal health insurance scheme and private funds, the cost of pharmaceuticals and over-the-counter medications, allied health services, research and health administration. The other financial costs of delirium in this study include productivity costs, informal care, funeral costs and deadweight losses associated with taxation payments and administration. The loss of well-being due to delirium was measured using disability adjusted life years (DALYs). A targeted literature review was conducted to identify the prevalence of delirium in acute hospitalisations, nursing homes and in the community (without presenting to hospital). The review also covered costs, productivity and other outcomes (eg, mortality and burden of disease) due to delirium. The targeted review was investigative in nature and considered fit-for-purpose as the prevalence and methods vary widely across studies. Searches were conducted using PubMed in June 2017. Studies were included if they were conducted in a hospital setting, and covered general hospital wards (medical or surgical) reflective of an acute setting. Studies were also included if they included costs of delirium, including health system, productivity, carer and well-being costs. Studies were excluded from the analysis if they did not measure prevalence using validated diagnostic measures, or if they did not report on costs or outcomes from delirium. Studies were further excluded if they did not report on primary or administrative data. No specific date restrictions were applied to the literature review due to the investigative nature of it. The specific search terms used in the literature review are available in online supplementary additional file 1. Results from the literature searches were generally pooled by taking a weighted average of outcomes or results. Additional grey literature (eg, government statistics) were also collated and these documents provide many of the necessary inputs for this cost of illness study.

Prevalence

The prevalence of delirium in Australian hospitals was estimated by taking a weighted average across identified studies (see online supplementary additional file 1, table 1). Prevalence was then applied to overnight acute emergency hospital separations for people aged 70 years or older in 2016–17 to estimate separations due to delirium in elderly people in that year.17 The number of separations in younger age groups (less than 70 years old) where delirium is recorded as an additional diagnosis were estimated by applying the ratio between total and principal delirium diagnoses to principal diagnoses in the younger age groups.17 18 No prevalence studies in Australian nursing homes were identified. Prevalence results were thus derived from a study from the Netherlands,19 due to similarities in aged care settings, demographic profiles and medication prescribing rates – for example, both countries exhibit high rates of psychotropic medication prescribing (though there are some differences in the preferred antipsychotic agent),20 despite their limited efficacy and adverse effects in people with delirium.7 The combined prevalence and incidence was 8.5% and 16.9 per 100 person-years respectively. These rates are similar to the rates reported in other international literature.21–23 These rates were applied to the number of permanent residents in aged care facilities in Australia, adjusting for population growth by age group from the Australian Bureau of Statistics (ABS).24 The total prevalence of delirium in Australia 2016–17 was adjusted to avoid double counting people in the residential aged care cohort who also present to hospital. The following rates were used to adjust the prevalence to avoid double counting people in residential aged care who also present to hospital: 50% of cases were delirious at admission25; 43% of hospitalised patients with delirium during their stay were delirious at discharge (5.5% delirious at discharge, 12.7% with delirium)26; 31.2% were admitted from residential aged care while 68.9% were admitted from the community27; and of people with delirium, 28% of patients were discharged to residential aged care, 63% were discharged to the community, and 9% died before discharge from hospital.28

Average duration of an episode of delirium and mortality

The average duration of delirium was estimated by taking a weighted average of the findings reported in twelve studies (online supplementary additional file 1, table 2). Mortality associated with delirium was estimated using an attributable fraction approach,13 and a HR of 1.77 that was based on a previous systematic review and meta-analysis (online supplementary additional file 1, table 3).3 The HR was used to estimate an attributable fraction for how many deaths are due to delirium in Australia.

Healthcare system expenditure

Health system costs were estimated using a bottom-up approach. This includes costs associated with hospital, medication, and research expenditure, out of hospital medical and other health professionals’ expenditure, and residential aged care expenditure. Delirium induces functional decline, resulting in a longer length of stay (LOS) for older people in hospital, consequently leading to higher hospitalisation expenditure.2 To estimate the additional expenditure, the prevalence of delirium among hospitalised older people was applied to the additional LOS and the average daily cost of care in a hospital setting. The average daily cost of an acute separation was obtained from the Independent Hospital Pricing Authority (IHPA) for 2014–15 and adjusted by the standard index rate used by IHPA (2.1%) to estimate the cost for the 2016–17 base year.29 The average daily cost was also adjusted by an additional 14.3% to inflate for non-allocated health costs (an allowance for capital costs) based on AIHW.30 Delirium can also be recorded as an additional diagnosis in Australian hospital data, where delirium contributes to a greater length of stay in hospital. The cost associated with an increased length of stay was estimated using the average daily cost of any hospital separation, which was further adjusted to remove separation costs that are unlikely to be attributable to delirium, such as costs associated with surgery. Where delirium was a primary diagnosis, the cost was assumed to be the same as the delirium diagnostic resource group, which was £4489 in 2016–17 after updating for inflation in the National Efficient Price.29 Health research expenditure on delirium in Australia in 2016–17 was estimated using data from the National Health and Medical Research Council (NHMRC) grants database. The database outlines all NHMRC research grant funding between 2000 and 2016 and provides a description of the projects and key outcomes achieved.31 Annual funding allocated to delirium research in 2016–17 was estimated by taking an average across the historical years. Other forms of health research where research costs can be recovered – for example, by charging a higher price for services – were not considered in this analysis, consistent with standard methodology.13 Out of hospital medical expenditure (GP consultations) was estimated by applying the average cost per GP consultation (approximately £16 after adjusting for multiple problems per GP consultation) to the total services associated with organic psychoses in Australia,32 33 which was considered comparable to delirium. Residential aged care expenditure was estimated using an attributable fraction approach based on literature to estimate admissions to aged care due to cognitive decline associated with delirium. The OR for admission (2.41),4 was converted to an attributable fraction. The number of admissions was adjusted by average LOS in residential aged care in Australia and applied to the average costs associated with residential aged care, which is approximately £43 978 per person in aged care.34

Other financial costs

The economic cost of short run productivity losses associated with absenteeism were estimated using the friction cost method.13 The absenteeism cost due to delirium was estimated by multiplying the average duration of delirium by the number of hospital separations that occur in the working age population, adjusted for general population employment rates. Average employment rates and average weekly earnings for people with delirium are based on ABS data for the general population by age and gender.35 36 Carers are people who provide care to others in need of assistance or support. An informal carer provides this service without formal payment and does so outside of the formal care sector. Evidence suggests that people with delirium experience a decline in functioning, such that they are unable to perform as many usual activities of daily living following delirium.37 38 Estimates of the hours of informal care provided to people with delirium was based on this expected decline in activities of daily living. The dollar value of informal care was estimated as the opportunity cost of a carer’s time, which was based on general population average weekly earnings and employment rates.35 36 The additional cost of funerals borne by family and friends of people with delirium was based on the number of deaths associated with delirium. The cost of a funeral was assumed to be £4602. Funeral costs were brought forward by the average life expectancy at age of death. The deadweight losses due to lost taxation revenue (given an assumption of no change in spending) and additional government spending on delirium was calculated by applying the average marginal excess burden of taxation of £0.31 per £1 of tax.39 40

Loss of well-being

Burden of disease methodology was employed to quantify the impact of delirium on well-being.41 The approach is non-financial, where pain, suffering and premature mortality are measured in terms of disability adjusted life years (DALYs). DALYs are comprised of years of healthy life lost due to morbidity (YLDs) and years of life lost due to premature mortality (YLLs).41 YLDs were calculated using a prevalence approach, whereby the disability weight was multiplied by average duration of delirium. The disability weight for delirium used in this study was 0.17.42 Duration of delirium was based on the prevalence of persistent delirium over 12 months.43 DALYs were converted to a monetary value using the value of a statistical life year (£93 882), which is an official estimate updated for inflation using the Consumer Price Index.44 The value of a statistical life year was discounted at a rate of 3% per annum,13 where it was applied to future years of life lost due to mortality from delirium.

Costs of dementia attributable to delirium

Costs of dementia were sourced from an Australian cost of illness study.45 Inputs were taken for Australia in the 2016 financial year, and updated using either health inflation or the Consumer Price Index as appropriate. The well-being cost attributable to dementia for YLLs or YLDs was estimated using data from the Australian Institute of Health and Welfare’s Australian Burden of Disease Study.46 The proportion of dementia attributable to delirium was estimated using the population attributable fraction approach. The OR for developing a new case was 5.88 for people aged 65–84 years old and 7.56 for people aged 85 years or older,47–49 which was used to estimate the attributable fraction.

Sensitivity analysis

One-way sensitivity analyses were conducted on prevalence, the risk for mortality, dementia admission to aged care, average hospital costs, discount rate for DALYs, and the value of a statistical life year. The specific values represent the upper and lower 95% confidence intervals for the relevant input parameters where available, or unit costs that were 25% higher or lower if the distribution was unknown.

Currency standardisation

All costs are expressed in 2016–17 pound sterling. Costs were converted from Australian dollars using the 2017 Organisation for Economic Cooperation and Development purchasing power parity of 2.065 Australian dollars per pound sterling in 2017.50

Data analysis and ethical considerations

Data for this study was collected throughout January to June 2017 by the authors from a range of public data sources and literature. The data was analysed and compiled in Microsoft Excel. No individual patient data was collected for the study and therefore, this study did not require ethics approval.

Patient and public involvement

Patient and public were not involved in the design or planning of this study.

Results

Prevalence and mortality

Overall, the prevalence of delirium in a hospital setting was estimated to be 20.2% on average, which was applied to the 521 099 overnight acute emergency hospital separations for people aged 70 years or older in 2016–17. Therefore, there were an estimated 105 182 hospital separations involving delirium in 2016–17, of which delirium was recorded as the principal diagnosis for approximately 11 999 separations in 2016–17. In addition, there were an estimated 14 578 separations for younger Australians, and 119 760 total cases of delirium in Australian hospitals in 2016–17. In Australia on 30 June 2015, there were 172 044 permanent residents in aged care facilities. There were an estimated 181 314 permanent residents in Australian aged care facilities on 30 June 2017 after adjusting for population growth by age group. Applying the prevalence (at baseline), and the incidence per 100 person years from Boorsma et al,19 it was estimated that 46 054 permanent residents had at least one episode of delirium in 2016–17. After adjusting for the interactions between delirium in aged care and hospital settings, there were an estimated 132 595 cases of delirium in Australia in 2016–17, representing cases that occur in both settings. This is equivalent to approximately 0.5% of the population in Australia, although some individuals may experience delirium more than once in a year. Prevalence by age and gender are available in table 1. The rates increase substantially with age.
Table 1

Estimated prevalence of delirium in Australia, 2016–17

Age/ genderCommunityResidential aged careTotal% of general population
Male
 <653278175650340.05
 65–691916128131970.5
 70–744342208864301.4
 75–896282286891492.8
 80–849680354513 2256.3
 85+18 651326321 91411.8
 Total44 14914 80158 949 0.5
Female
 <65410074648460.05
 65–69199477827730.5
 70–744044152355671.1
 75–796224277189962.5
 80–849195527014 4655.5
 85+16 83520 16436 99911.9
 Total42 39331 25373 646 0.6
Person 86 541 46 054 132 595 0.5
Estimated prevalence of delirium in Australia, 2016–17 The HR for mortality indicated that 12 571 people who had delirium would die, and an estimated 909 deaths were attributable to delirium itself in 2016–17. Delirium most commonly occurred in hospitals in Australia in 2016–17, with an estimated 119 760 cases (some of these individuals usually reside in aged care). Delirium was recorded as the primary diagnosis in 13 662 separations at an average cost of £4489 per separation in 2016–17. Delirium was recorded as an additional diagnosis in a further 106 098 separations. The average daily cost for an additional separation was estimated to be £644, which was multiplied by the number of cases and the additional LOS due to delirium, which was estimated to be 2.7 days (see online supplementary additional file 1, table 4 and table 5). After adjusting for population growth, there were estimated to be 22 640 GP consultations associated with delirium in 2016–17, which was multiplied by £16 per consultation to estimate total GP costs. Total health system and aged care costs associated with delirium in Australia were estimated to be £844.2 million in 2016–17. The total comprised hospital (£247.3 million), residential aged care (£596.2 million), out-of-hospital medical (£0.4 million), and research expenditure (£0.3 million). On average, it was estimated that each person with delirium received an additional 0.9 hours of care per week, based on the change in activities of daily living over a period of 12 months (online supplementary additional file 1 provides supplementary information that was used to estimate the additional hours of care). Thus, informal carers provided an estimated 987 958 hours of care in 2016–17, which was valued at £0.8 million. The cost of informal care (£0.8 million) is relatively small due to the low opportunity cost of carer time (£0.84 per hour). We estimate that working age people with delirium were absent from work for 44 590 days in 2016–17, which was valued at £6.6 million using average weekly earnings for the general population. Finally, brought forward funeral costs were estimated to be £0.7 million and deadweight losses were estimated to be £188.4 million in Australia 2016–17. Thus, total other financial costs (informal care, absenteeism, brought forward funeral costs and deadweight losses) were estimated to be £196.6 million in Australia in 2016–17. Productivity losses imposed by delirium were estimated to be relatively small as delirium largely occurs in the elderly population. The total burden of disease from delirium in 2016–17 was estimated to be £994.1 million. Overall, delirium resulted in an estimated: 5441 years of healthy life lost due to disability (YLDs), or 0.041 YLDs per person with delirium; 5687 years of life lost due to premature death (YLLs), or 0.043 YLLs per person with delirium; and 11 128 DALYs overall, or around 0.084 DALYs per person with delirium in 2016–17. Overall, it was estimated that 40 981 (10.6%) cases of dementia were attributable to delirium, which largely occur in people aged 85 years or older. The total costs of dementia due to delirium were estimated to be £2.2 billion in Australia in 2016–17, of which the financial costs were £675.7 million and the loss of well-being was £1.6 billion. table 2 shows cost breakdowns by age and gender group. Figure 1 shows the costs of dementia due to delirium broken down by health system and aged care costs, other financial costs and burden of disease.
Table 2

Estimated costs of delirium in Australia in 2016–2017, by age and gender group, £ million or %

Age/ genderFinancial costWell-being costTotal% of total
DeliriumDementia due to deliriumDeliriumDementia due to delirium
Male
 <6515.019.534.51
 65–698.17.912.65.133.71
 70–7457.522.326.818.2124.83
 75–8981.948.243.767.6241.46
 80–84124.667.989.5126.3408.410
 85+233.5154.1260.6368.21016.324
Female
 <6514.718.733.41
 65–697.09.810.87.234.81
 70–7452.214.622.413.8103.02
 75–7981.047.139.772.2240.06
 80–84121.971.180.3144.0417.410
 85+243.3232.9369.4729.01574.637
Overall 1040.8 675.7 994.1 1551.6 4262.2 100
% of total 24 16 23 36 100
Figure 1

Costs of delirium and dementia due to delirium in Australia in 2016–17, £ million.

Estimated costs of delirium in Australia in 2016–2017, by age and gender group, £ million or % Costs of delirium and dementia due to delirium in Australia in 2016–17, £ million.

Total costs

The total costs of delirium in Australia were estimated to be £4.3 billion ($A8.8 billion) in 2016–17. The total cost comprised financial costs of £1.7 billion ($A3.5 billion) and the value of healthy life lost of £2.5 billion ($A5.3 billion). table 3 shows the costs of delirium broken down by health system and aged care costs, other financial costs, and burden of disease.
Table 3

Estimated costs of delirium in Australia in 2016–17, by cost component

Cost componentTotal (£ million)Per person with delirium (£)
Health system and aged care1299.99804
Other financial costs416.63142
Loss of well-being2545.719 199
Total costs4262.232 145
Estimated costs of delirium in Australia in 2016–17, by cost component The results and specific values for the sensitivity analysis are shown in table 4 and figure 2. The total cost of delirium in Australia was most sensitive to changes in the risk for dementia following delirium and the overall prevalence rate. The total cost of delirium was estimated to range from £2.6 billion to £5.9 billion in Australia in 2016–17.
Table 4

Sensitivity analysis, £ million

VariableFinancialLoss of well-beingTotal
Base case1716.52545.74262.2
Prevalence (20.2%)
Lower (17.0%)1333.32110.63443.9
Upper (23.3%)2141.12993.65134.7
Risk for mortality (OR=1.77)
Upper (OR=2.15)1716.82757.94474.8
Lower (OR=1.39)1716.22316.74032.9
Risk for dementia (OR for >65 = 5.88, OR for >85 = 7.56)
Upper (OR for >65 = 20.70, OR for >85 = 29.43)2191.03678.25869.2
Lower (OR for >65 = 1.69, OR for >85 = 1.96)1213.01372.82585.8
Risk for admission to aged care (OR=2.41)
Upper (OR=3.29)1993.32545.74539.0
Lower (OR=1.77)1453.82545.73999.6
Average hospital costs*
Upper (+25%)1794.72545.74340.4
Lower (−25%)1638.42545.74184.1
Discount rate for DALYs (3%)
Upper (7%)1716.52488.64205.1
Lower (0%)1716.52596.34312.9

*Hospital costs were varied for delirium only, not dementia.

Figure 2

Sensitivity analysis (tornado diagram) showing the impact of key parameter inputs on the total cost of delirium in Australia in 2016–2017.

Sensitivity analysis, £ million *Hospital costs were varied for delirium only, not dementia. Sensitivity analysis (tornado diagram) showing the impact of key parameter inputs on the total cost of delirium in Australia in 2016–2017.

Discussion

This is the first cost of illness study estimating the economic impact of delirium in the Australian population. While a number of studies have examined the financial costs of delirium, they are generally limited to specific services or population subgroups.5 There have been no previous attempts to estimate the cost of delirium taking into account both the financial and well-being costs, as this study has done. It is critical that such economic estimations are undertaken as they inform decision making. According to these estimates, delirium imposes a substantial burden on society. Considering delirium alone, the economic costs were mostly incurred by the health and aged care systems (£844.2 million), representing close to 1.5% of total expenditure on health and aged care in Australia. As many high-income western countries are dealing with issues of ageing demographics and cognitive impairment, the findings may be generalizable to other health and aged care systems. For example, previous research has found that delirium is associated with multiple adverse outcomes including increased length and cost of hospitalisation, functional and cognitive decline, institutionalisation, and mortality.2–5 51 These results have significant implications for governments, who aim to identify conditions with high social and financial costs for focused attention through public education and other initiatives that effect improvements in health status. The results of this study highlight the need for concerted, worldwide efforts to mitigate the impacts of this clinically significant and costly medical condition. According to these estimates, there were 132 595 occurrences of delirium in Australia in 2016–17, but data from the Australian Institute of Health and Welfare National Hospital Morbidity Database for 2015–16 indicate that as many as 1 in five cases are missed. This is supported by previous research which suggests that delirium is undiagnosed in a large number of cases, ranging from approximately 25% of cases up to 87.5% in cases where dementia is also present.12 This has significant implications for clinical practice as the outcomes of delirium are serious.1 Future research could focus on techniques to improve the detection rate. Dementia represents a significant cost to the economy of all countries; the cost of dementia due to delirium is therefore an important cost component of delirium. It has been estimated that 47 million people are living with dementia globally, with costs of £583 billion in 2015 (original estimate converted from US dollars to pound sterling using purchasing power parity of 0.713)50 52; moreover, prevalence is expected to triple over the next three decades.52 Overall, the costs of dementia attributable to delirium more than doubled the total costs of delirium in Australia in 2016–17. It was estimated that approximately 10.6% of dementia cases, and thus costs, are associated with delirium. Therefore, delirium imposes a large cost burden on residential aged care, due to the high prevalence of dementia and the strong relationships between cognitive impairment and aged care. There may be considerable opportunities to prevent some of the worldwide burden of dementia and improve the fiscal sustainability of health systems in the face of ageing populations. Care for delirium following discharge from hospital relies heavily on informal carers, who provided almost 1 million hours of care to people with delirium. As workforce participation increases and the propensity to care declines,53 there is a risk that the care needs of people with delirium will either go unmet, or require additional government funding for aged care to meet their needs. There are some limitations to this study. First, the methods outlined the use of a non-systematic search strategy, noting that this was fit-for-purpose when a number of inputs were derived from official Australian Government statistics. The estimates presented should be interpreted with this in mind. Second, limited studies were found with appropriate methods to robustly estimate the prevalence of delirium in Australian hospital settings, but also in community or residential aged care settings. In order to minimise the impact of this limitation and the risk of double counting across studies, the analysis focused on delirium which met the full diagnostic criteria. Similarly, data paucity in some areas, such as out-of-hospital medical costs and productivity losses (employment outcomes) means that total estimates may be conservative. Given the methodology, the costs of delirium presented in this paper should be treated as an estimate only. More research, including observational studies in Australian settings, is required to understand the true costs incurred by people with delirium. However, a study that can capture costs across the health system and aged care settings in Australia will be technically challenging and may not be feasible due to the fragmented nature of the systems and data collection – particularly beyond the point at which people interact with the system. Finally, cost of illness studies provide guidance on the size of the problem, but are only useful for informing cost effective options for change when compared with the cost of such interventions. More work is needed to identify cost effective options to reduce the burden of delirium in Australia.

Conclusion

In summary, delirium imposes a substantial burden on Australian society – both in terms of financial costs associated with health system expenditure and a greater need for residential aged care due to the functional and cognitive decline associated with delirium and dementia. The financial costs of delirium were largely borne by Australian governments due to the health system and aged care expenditure. Further research should seek to understand the causes, treatment and prognosis of delirium, especially with regard to potential pathways from an episode of delirium to subsequent mortality outcomes and reduced cognitive functioning. Improving mortality outcomes and reducing decline in cognitive functioning would help to reduce the substantial financial and well-being costs of delirium.
  31 in total

Review 1.  Review: delirium in the elderly: a comprehensive review.

Authors:  Vikrant Mittal; Sunanda Muralee; Deena Williamson; Nicole McEnerney; Jennifer Thomas; Mary Cash; Rajesh R Tampi
Journal:  Am J Alzheimers Dis Other Demen       Date:  2011-01-31       Impact factor: 2.035

Review 2.  Persistent delirium in older hospital patients: a systematic review of frequency and prognosis.

Authors:  Martin G Cole; Antonio Ciampi; Eric Belzile; Lihong Zhong
Journal:  Age Ageing       Date:  2008-11-18       Impact factor: 10.668

3.  Cross-national comparison of medication use in Australian and Dutch nursing homes.

Authors:  Katja Taxis; Sjoerd Kochen; Hans Wouters; Froukje Boersma; Maring Jan Gerard; Hans Mulder; Jugoslav Pavlovic; Gerard Stevens; Andrew McLachlan; Lisa G Pont
Journal:  Age Ageing       Date:  2017-03-01       Impact factor: 10.668

4.  Older adults discharged from the hospital with delirium: 1-year outcomes.

Authors:  Gail J McAvay; Peter H Van Ness; Sidney T Bogardus; Ying Zhang; Douglas L Leslie; Linda S Leo-Summers; Sharon K Inouye
Journal:  J Am Geriatr Soc       Date:  2006-08       Impact factor: 5.562

5.  An 18-month prospective cohort study of functional outcome of delirium in elderly patients: activities of daily living.

Authors:  Stephen Vida; Guillaume Galbaud du Fort; Ritsuko Kakuma; Louise Arsenault; Robert W Platt; Christina M Wolfson
Journal:  Int Psychogeriatr       Date:  2006-04-27       Impact factor: 3.878

6.  Premature death associated with delirium at 1-year follow-up.

Authors:  Douglas L Leslie; Ying Zhang; Theodore R Holford; Sidney T Bogardus; Linda S Leo-Summers; Sharon K Inouye
Journal:  Arch Intern Med       Date:  2005-07-25

7.  Delirium in elderly patients and the risk of postdischarge mortality, institutionalization, and dementia: a meta-analysis.

Authors:  Joost Witlox; Lisa S M Eurelings; Jos F M de Jonghe; Kees J Kalisvaart; Piet Eikelenboom; Willem A van Gool
Journal:  JAMA       Date:  2010-07-28       Impact factor: 56.272

8.  Dementia after delirium in patients with femoral neck fractures.

Authors:  Maria Lundström; Agneta Edlund; Gösta Bucht; Stig Karlsson; Yngve Gustafson
Journal:  J Am Geriatr Soc       Date:  2003-07       Impact factor: 5.562

Review 9.  Factors associated with prolonged delirium: a systematic review.

Authors:  Monidipa Dasgupta; Loretta M Hillier
Journal:  Int Psychogeriatr       Date:  2010-01-21       Impact factor: 3.878

10.  One-year health care costs associated with delirium in the elderly population.

Authors:  Douglas L Leslie; Edward R Marcantonio; Ying Zhang; Linda Leo-Summers; Sharon K Inouye
Journal:  Arch Intern Med       Date:  2008-01-14
View more
  10 in total

1.  Developing delirium best practice: a systematic review of education interventions for healthcare professionals working in inpatient settings.

Authors:  Song Yuin Lee; James Fisher; Anne P F Wand; Koen Milisen; Elke Detroyer; Sanjeev Sockalingam; Meera Agar; Annmarie Hosie; Andrew Teodorczuk
Journal:  Eur Geriatr Med       Date:  2020-01-14       Impact factor: 1.710

Review 2.  Non-Pharmacological Nursing Interventions to Prevent Delirium in ICU Patients-An Umbrella Review with Implications for Evidence-Based Practice.

Authors:  Sandra Lange; Wioletta Mędrzycka-Dąbrowska; Adriano Friganovic; Ber Oomen; Sabina Krupa
Journal:  J Pers Med       Date:  2022-05-07

3.  Alpha-2-adrenergic receptor agonists for the prevention of delirium and cognitive decline after open heart surgery (ALPHA2PREVENT): protocol for a multicentre randomised controlled trial.

Authors:  Bjørn Erik Neerland; Rolf Busund; Rune Haaverstad; Jorunn L Helbostad; Svein Aslak Landsverk; Ieva Martinaityte; Hilde Margrethe Norum; Johan Ræder; Geir Selbaek; Melanie R Simpson; Elisabeth Skaar; Nils Kristian Skjærvold; Eva Skovlund; Arjen Jc Slooter; Øyvind Sverre Svendsen; Theis Tønnessen; Alexander Wahba; Henrik Zetterberg; Torgeir Bruun Wyller
Journal:  BMJ Open       Date:  2022-06-20       Impact factor: 3.006

Review 4.  Current Challenges in the Recognition and Management of Delirium Superimposed on Dementia.

Authors:  Anita Nitchingham; Gideon A Caplan
Journal:  Neuropsychiatr Dis Treat       Date:  2021-05-05       Impact factor: 2.570

5.  The DEMS-DOSS study: validating a delirium monitoring tool in hospitalised older adults.

Authors:  Amy Montgomery; Jo-Anne Todd; Cindy Jones; June Koroitamana; Laurie Grealish; Anne Wand; Stephen Billett; Andrew Teodorczuk
Journal:  Age Ageing       Date:  2022-02-02       Impact factor: 12.782

6.  Effects of non-pharmacological interventions for preventing delirium in general ward inpatients: A systematic review & meta-analysis of randomized controlled trials.

Authors:  Yun Hee Kim; Nam Young Kim; Seang Ryu
Journal:  PLoS One       Date:  2022-05-06       Impact factor: 3.752

7.  DelIrium VULnerability in GEriatrics (DIVULGE) study: a protocol for a prospective observational study of electroencephalogram associations with incident postoperative delirium.

Authors:  Monique S Boord; Daniel H J Davis; Peter J Psaltis; Scott W Coussens; Daniel Feuerriegel; Marta I Garrido; Alice Bourke; Hannah A D Keage
Journal:  BMJ Neurol Open       Date:  2021-12-06

8.  Commentary: Prevention and management of delirium in older Australians: The need for the integration of carers as partners in care.

Authors:  Christina Aggar; Alison Craswell; Kasia Bail; Roslyn M Compton; Khoka Hamiduzzaman; Golam Sorwar; Mark Hughes; Jennene Greenhill; Lucy Shinners; James R Baker
Journal:  Lancet Reg Health West Pac       Date:  2022-09-15

9.  Demographic and clinical characteristics of patients with delirium: analysis of a nationwide Japanese medical database.

Authors:  Naoya Ueda; Masakazu Igarashi; Kotoba Okuyama; Hideki Sano; Kanae Takahashi; Zaina P Qureshi; Shigeru Tokita; Asao Ogawa; Yasuyuki Okumura; Shoki Okuda
Journal:  BMJ Open       Date:  2022-09-14       Impact factor: 3.006

10.  The delirium screening tool 4AT in routine clinical practice: prediction of mortality, sensitivity and specificity.

Authors:  Sigurd Evensen; Anette Hylen Ranhoff; Stian Lydersen; Ingvild Saltvedt
Journal:  Eur Geriatr Med       Date:  2021-04-04       Impact factor: 1.710

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.